Athersys

Athersys Stock-Based Compensation

Delisted·Oct 1, 2026

The Stock-Based Compensation (SBC) of Athersys (ATHXQ) as of Nov 20, 2026 is 6.20 M USD. In the previous year, Stock-Based Compensation (SBC) was 8.56 M USD — a change of -27.50% (lower).

Stock-Based Compensation

6.20 MUSD

YoY

-27.50%

Last updated:

Stock-Based Compensation (SBC) of Athersys is 2022 6.20 M USD. Stock-Based Compensation (SBC) of Athersys was 2021 8.56 M USD. It decreases by -27.50% lower compared to the previous year.

The Athersys Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2015
2.93 M USD
Jan 1, 2016
2.87 M USD
Jan 1, 2017
3.04 M USD
Jan 1, 2018
3.85 M USD
Jan 1, 2019
4.85 M USD
Jan 1, 2020
7.38 M USD
Jan 1, 2021
8.56 M USD
Jan 1, 2022
6.20 M USD
The Athersys Stock-Based Compensation history
YEARStock-Based CompensationYoY
6.20 MUSD-27.50%
8.56 MUSD+15.95%
7.38 MUSD+52.11%
4.85 MUSD+26.03%
3.85 MUSD+26.45%
3.04 MUSD+6.14%
2.87 MUSD-2.08%
2.93 MUSD+12.44%
2.61 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Stock-Based Compensation (SBC) of Athersys is 6.20 M USD in 2022.

Stock-Based Compensation (SBC) of Athersys changed from 8.56 M USD to 6.20 M USD, representing a -27.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Athersys since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Athersys

All Key Metrics — Athersys